Jung-Wook Chin

Introduction: Jung-Wook Chin, based in Daegu, South Korea, is an accomplished inventor with a focus on pharmaceutical innovations. With a patent that demonstrates his expertise in medicinal chemistry, he contributes significantly to treatments targeting various health conditions.

Latest Patents: Jung-Wook Chin holds a notable patent for a compound described as a 2-cyanopyrimidin-4-yl carbamate or urea derivative. This patent outlines a process for preparing the compound and includes a pharmaceutical composition comprising it. The innovative aspect of this compound is its selective inhibition of cathepsin K, which positions it as a valuable candidate in the prevention and treatment of osteoporosis.

Career Highlights: Jung-Wook is associated with Hanlim Pharmaceutical Co., Ltd., where his work in pharmaceutical development aligns with his inventive pursuits. His research is geared towards creating effective therapeutic agents that address critical health concerns, showcasing his commitment to advancing medical science.

Collaborations: Throughout his career, Jung-Wook Chin has collaborated with esteemed colleagues like Kyung-Hee Kim and Ji-Hoon Lee. Their teamwork in research and development contributes to the successful innovation of pharmaceutical products and enhances the overall impact of their efforts in the industry.

Conclusion: Jung-Wook Chin exemplifies the spirit of innovation in pharmaceutical science. His patent for the 2-cyanopyrimidin-4-yl carbamate or urea derivative underscores his dedication to developing new treatments for osteoporosis. As he continues his work at Hanlim Pharmaceutical Co., Ltd., Jung-Wook remains a key figure in advancing health solutions through innovative research and collaboration.

Profile summary based on public USPTO records.